Tradestie Institutional Equity Comparison Engine

SLGB vs CYRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CYRX Overall Edge

CYRX Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CryoPort, Inc. Common Stock (CYRX) driven by superior Valuation, Momentum & Technical, Options & Structure while SLGB counters with relative strength in Growth & Margin. Fundamentally, SLGB trades at N/M Forward P/E with -2.3% operating margin (-22.1% YoY revenue) versus CYRX at 93.5x Forward P/E and -14.4% operating margin (+13.5% YoY). In options structure, SLGB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CYRX sits in BREAKOUT (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CYRX
SLGB N/M vs CYRX 93.5x Fwd P/E
Growth & Margin Winner SLGB
Op Margin -2.3% vs -14.4% ยท YoY -22.1% vs +13.5%
Momentum & Technical Winner CYRX
1Y -90.8% vs +124.2% ยท 52W Pos 1% vs 85%
Options & Structure Winner CYRX
UNCLASSIFIED (N/A IV) vs BREAKOUT (6th %ile IV)
SLGB US Equity
SLGB
Institutional Equity
$0.18
+1.98% 1D
Market Cap $8.1M
1M Return -15.53%
1Y Return -90.75%
Forward P/E N/M
Unified AI Score
47.2 / 100 HOLD
Tech 55.0 Fund 53.0 Flow 50.0 Mom 64.0
CYRX NASDAQ
CryoPort, Inc. Common Stock
Pharmaceutical Preparations
$19.64
-1.26% 1D
Market Cap $1.0B
1M Return +16.63%
1Y Return +124.2%
Forward P/E 93.5x
Unified AI Score
36.5 / 100 SELL
Tech 50.0 Fund 40.0 Flow 64.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SLGB -90.75% CYRX +124.2% Spread: +214.95 pp (CYRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SLGB TTM Op. Margin: -2.3% CYRX TTM Op. Margin: -14.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLGB vs CYRX. Trailing 12-month operating profitability (SLGB -2.3% vs CYRX -14.4%) and valuation multiples (SLGB N/M vs CYRX 93.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SLGB (3) vs CYRX (7)
Institutional Metric SLGB CYRX Criterion Row Winner
Market Capitalization Scale $8.1M $1.0B Larger Scale CYRX
Trailing P/E Ratio Valuation N/M 93.5x Lower Multiple CYRX
Forward P/E Ratio Valuation N/M 93.5x Lower Multiple CYRX
Revenue Growth (YoY) Growth -22.1% +13.5% Higher Growth CYRX
Operating Margin (TTM) Profitability -2.3% -14.4% Higher Margin SLGB
Net Profit Margin Profitability -2.9% -21.5% Higher Margin SLGB
Return on Equity (ROE) Capital Efficiency -14.7% -7.4% Higher ROE CYRX
52-Week Range Position Momentum 1% ($0โ€“$4) 85% ($8โ€“$22) Stronger Trend CYRX
Beta / 30D Volatility Risk Regime -0.05ฮฒ ยท 207% Vol 1.58ฮฒ ยท 85% Vol Lower Realized Risk CYRX
Unified Institutional Score Composite Signal 47.2 / 100 (HOLD) 36.5 / 100 (SELL) Higher Composite SLGB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SLGB vs CYRX Buy Guide
SLGB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SLGB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CYRX BREAKOUT
115d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live CYRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SLGB nor CYRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.